Fat cell function and fibrinolysis

Hormone and Metabolic Research

Volumn 32, Issue 11-12, 2000, Pages 504-508

  Alessi, M C ^a   Morange, P ^a   Juhan Vague, I ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Adipose Tissue; Insulin Resistance; PAI 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOCYTE; ATHEROGENESIS; CORONARY RISK; FIBRINOLYSIS; HUMAN; INSULIN RESISTANCE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW;

EID: 0034470195     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978677     Document Type: Review

References (62)

1. Basic and clinical aspects of fibrinolysis and thrombolysis
2. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
3. Fibrinolysis and risk of coronary artery disease
4. Clearance of t-PA and t-PA/PAI-1 complex: Relationship to elevated t-PA antigen in patients with high PAI-1 activity levels
5. Fibrinogen, plasminogen activator inhibitor-1, a carotid intima-media wall thickness in the NHLBI family heart study
6. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function
7. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
8. Endogenous tissue type plasminogen activator and risk of myocardial infarction
9. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
10. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
11. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
12. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
13. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprobol
14. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
15. Plasma plasminogen activator inhibitor I in angina pectoris. Influence of plasma insulin and acute-phase response
16. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
17. Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women
18. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1: Implications for vascular disease by hyperinsulinemic states
19. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non insulin dependent) diabetic subjects
20. PAI-1 obesity and insulin resistance
21. Haemostasis factors in angina Pectoris: Relation to gender, age and acute-phase reaction
22. Role of insulin resistance in human disease
23. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland
24. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population
25. Hyperinsulinemia as an independent risk factor for ischemic heart disease
26. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men
27. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women
28. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity
29. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension
30. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo; tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, transforming growth factor-β
31. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
32. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
33. Adipose tissue secretion of plasminogen activator inhibitor-1 in non obese and obese individuals
34. Expression of plasminogen activator inhibitor 1 in human adipose tissue
35. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture
36. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice
37. Protection from obesity-induced insulin resistance in mice lacking TNF alpha function
38. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity
39. Adipose expression of tumor necrosis factor α: Direct role of obesity-linked insulin resistance
40. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1
41. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice
42. Plasminogen activator inhibitor-1, transforming growth factor β1 and body mass index are closely associated in human adipose tissue during morbid obesity
43. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Possible contribution of local TNF-α and TGF-β
44. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss
45. Non alcoholic steatohepatitis
46. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - Role of the metabolic syndrome
47. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells
48. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2
49. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
50. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue
51. Intraperitoneal insulin administration does not modify plasminogen activator inhibitor 1 levels in IDDM patients
52. The fibrinolytic potential in patients with Cushing's disease: A clue to their hypercoagulable state
53. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation
54. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease
55. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes
56. Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1
57. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes
58. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide
59. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo
60. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and type 2 diabetic subjects
61. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity
62. Effect of disruption of the PAI-1 gene on body weight, insulin resistance and hyperinsulinemia in genetically obese mice